Form 4: Procept BioRobotics Executive Hisham Shiblaq Reports Stock Transactions

Hisham Shiblaq, EVP and Chief Commercial Officer of Procept BioRobotics, reports the acquisition and disposal of common stock and stock options.

Summary

• On March 6, 2024, Hisham Shiblaq, EVP and Chief Commercial Officer of Procept BioRobotics, reported transactions involving the company's stock.
• Shiblaq acquired 26,449 shares of common stock through restricted stock units (RSUs) at a price of $0.
• He also disposed of 1,759 shares of common stock at a weighted average price of $46.67 to cover tax withholding obligations related to the vesting of RSUs granted on February 16, 2023.
• Additionally, Shiblaq acquired stock options for 23,038 shares of common stock with an exercise price of $47.17.
• The RSUs vest in equal installments on the anniversary of March 5, 2024, over three years, contingent upon continued employment.
• The stock options vest monthly from March 5, 2024, over four years, also contingent upon continued employment.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing reporting stock transactions by an executive. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Future Outlook

The vesting of RSUs and stock options is contingent upon continued employment or service by the Reporting Person to the Issuer through the applicable vesting date.

Industry Context

This filing is a routine disclosure of stock transactions by a company executive, which is common in publicly traded companies. It provides transparency into the executive's holdings and transactions in the company's stock.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership of shares.
• Employees may be impacted as the vesting of RSUs and stock options is tied to continued employment.

Key Dates